Skip to main content
. 2001 Feb 13;98(5):2652–2657. doi: 10.1073/pnas.041603898

Figure 3.

Figure 3

NCX-1000 protects against liver damage induced by Fas agonistic mAb, Jo2. NCX-1000 reduces AST plasma levels and caspase 8-like activity in mice treated with Jo2. Data are mean ± SE of five experiments. *, P < 0.01 versus control. **, P < 0.01 versus Jo2 alone.